Hoarseness and Laryngopharyngeal Reflux A Survey of Primary Care Physician Practice Patterns

Similar documents
2012 Medicaid and Partnership Chart

ACEP National H1N1 Preparedness Survey Results

Prevalence of Self-Reported Obesity Among U.S. Adults by State and Territory. Definitions Obesity: Body Mass Index (BMI) of 30 or higher.

Peer Specialist Workforce. State-by-state information on key indicators, and links to each state s peer certification program web site.

2018 HPV Legislative Report Card

Obesity Trends:

Peer Specialist Workforce. State-by-state information on key indicators, and links to each state s peer certification program web site.

National Deaf Center on Postsecondary Outcomes. Data Interpretation Guide for State Reports: FAQ

Forensic Patients in State Hospitals:

Cirrhosis and Liver Cancer Mortality in the United States : An Observational Study Supplementary Material

The Rural Health Workforce. Policy Brief Series. Data and Issues for Policymakers in: Washington Wyoming Alaska Montana Idaho

Responses to a 2017 Survey on State Policies Regarding Community Health Workers: Home Visiting to Improve the Home Environment

STATE RANKINGS REPORT NOVEMBER mississippi tobacco data

States with Authority to Require Nonresident Pharmacies to Report to PMP

Medical Marijuana Responsible for Traffic Fatalities Alfred Crancer, B.S., M.A.; Phillip Drum, Pharm.D.

Percent of U.S. State Populations Covered by 100% Smokefree Air Laws April 1, 2018

If you suspect Fido's owner is diverting prescription pain meds meant for the pet, checking your state's drug monitoring database may not help

Using Policy, Programs, and Partnerships to Stamp Out Breast and Cervical Cancers

Average Number Citations per Recertification Survey

Opioid Deaths Quadruple Since 1999

Medical Advisory Board. reviews medical issues for licensure regarding individual drivers. medical conditions. not specified. reporting encouraged,

Georgina Peacock, MD, MPH

West Nile virus and other arboviral activity -- United States, 2013 Provisional data reported to ArboNET Tuesday, January 7, 2014

Radiation Therapy Staffing and Workplace Survey 2016

It's tick time again! Recognizing black-legged (deer ticks) and measuring the spread of Lyme disease

PETITION FOR DUAL MEMBERSHIP

-Type of immunity that is more permanent (WBC can Remember)

An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth

CDC activities with Autism Spectrum Disorders

Geographical Accuracy of Cell Phone Samples and the Effect on Telephone Survey Bias, Variance, and Cost

MAKING WAVES WITH STATE WATER POLICIES. Washington State Department of Health

DEPARTMENT OF DEFENSE (AFHSB)

MetLife Foundation Alzheimer's Survey: What America Thinks

Plan Details and Rates. Monthly Premium Rate Schedule

Trends in Lung Cancer Morbidity and Mortality

The 2004 National Child Count of Children and Youth who are Deaf-Blind

The Chiropractic Pediatric CE Credit Program with Emphasis on Autism

West Nile virus and other arboviral activity -- United States, 2016 Provisional data reported to ArboNET Tuesday, October 11, 2016

March 5, The Honorable John A. Boehner Speaker U.S. House of Representatives H-232 U.S. Capitol Building Washington, DC 20515

CDC activities Autism Spectrum Disorders

DEPARTMENT OF DEFENSE (AFHSB)

Hawai i to Zero. Timothy McCormick Harm Reduction Services Branch Hawai i Department of Health. January 16, 2018

DEPARTMENT OF DEFENSE (AFHSB) Seasonal Influenza Surveillance Summary Northern Command -- Week 17 (22 Apr 28 Apr 2018)

DEPARTMENT OF DEFENSE (AFHSB)

DEPARTMENT OF DEFENSE (AFHSB)

DEPARTMENT OF DEFENSE (AFHSB)

DEPARTMENT OF DEFENSE (AFHSB)

DEPARTMENT OF DEFENSE (AFHSB)

April 25, Edward Donnell Ivy, MD, MPH

NCQA did not add new measures to Accreditation 2017 scoring.

Instant Drug Testing State Law Guide

SUMMARY OF SYNTHETIC CANNABINOID BILLS

DEPARTMENT OF DEFENSE (AFHSB)

DEPARTMENT OF DEFENSE (AFHSB)

DEPARTMENT OF DEFENSE (AFHSB)

B&T Format. New Measures. Better health care. Better choices. Better health.

DEPARTMENT OF DEFENSE (AFHSB)

Autism Activities at CDC: The Public Health Model

Health Care Reform: Colorectal Cancer Screening Expansion, Before and After the Affordable Care Act (ACA)

DEPARTMENT OF DEFENSE (AFHSB)

ADVANCE FOR PHYSICAL THERAPY AND REHAB MEDICINE

American Association of Suicidology. Statistics AAS. Statistics. National Statistical Information FMHI. American Association of Suicidology (AAS)

Youth and Adult Marijuana Use

B&T Format. New Measures. 2 CAHPS is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).

Methamphetamines: A National and State Crisis. Research Brief. Prepared by

The Wellbeing of America s Workforce, and Its Effects on an Organization s Performance

Hepatitis C: The State of Medicaid Access. Preliminary Findings: National Summary Report

Medical Marijuana

HIV/AIDS and other Sexually Transmitted Diseases (STDs) in the Southern Region of the United States: Epidemiological Overview

2003 National Immunization Survey Public-Use Data File

Contents. Introduction. Acknowledgments. 1 Assisted Reproduction and the Diversity of the Modern Family 1. 2 Intrauterine Insemination 31.

AAll s well that ends well; still the fine s the crown; Whate er the course, the end is the renown. WILLIAM SHAKESPEARE, All s Well That Ends Well

DEPARTMENT OF DEFENSE (AFHSB)

Perinatal Health in the Rural United States, 2005

Save Lives and Money. Help State Employees Quit Tobacco

DEPARTMENT OF DEFENSE (AFHSB)

Results from the Commonwealth Fund Scorecard on State Health System Performance. Douglas McCarthy. Senior Research Director The Commonwealth Fund

Cessation and Cessation Measures

September 20, Thomas Scully Administrator Centers for Medicare and Medicaid Services 200 Independence Avenue SW Washington, DC 20201

Federation of State Boards of Physical Therapy Results of PT and PTA Program Textbook Survey

Quarterly Hogs and Pigs

HIV in Prisons, 2000

Quarterly Hogs and Pigs

DEPARTMENT OF DEFENSE (AFHSB)

Identical letters were also sent to Chairman/Ranking Member of the House Ways and Means Committee and House Energy and Commerce Committee

Analysis of State Medicaid Agency Performance in Relation to Incentivizing the Provision of H1N1 Immunizations to Eligible Populations

West Nile virus and other arboviral activity -- United States, 2014 Provisional data reported to ArboNET Tuesday, September 2, 2014

Prescription Drug Monitoring Program (PDMP) Delaware. Information contained in this presentation is accurate as of November 2017

Health Care Reform: Colorectal Cancer Screening Disparities, Before and After the Affordable Care Act (ACA)

CMS Oral Health Ini9a9ve - Goals

NM Coalition of Sexual Assault Programs, Inc.

Exhibit 1. Change in State Health System Performance by Indicator

ROAD SAFETY MONITOR. ALCOHOL-IMPAIRED DRIVING IN THE UNITED STATES Results from the 2017 TIRF USA Road Safety Monitor

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Chapter Two Incidence & prevalence

EMG Laws by State. needle EMGs and NCSs can be found in its position statement Who is Qualified to Practice EDX Medicine.

Public Health Federal Funding Request to Address the Opioid Epidemic

Radiation Therapy Staffing and Workplace Survey 2018

Transcription:

Research Original Investigation A Survey of Primary Care Physician Practice Patterns Ryan Ruiz, BA; Seema Jeswani, MD; Kenneth Andrews, MD; Benjamin Rafii, MD; Benjamin C. Paul, MD; Ryan C. Branski, PhD; Milan R. Amin, MD IMPORTANCE Current approaches to the diagnosis and subsequent management of specific voice disorders vary widely among primary care physicians (PCPs). In addition, sparse literature describes current primary care practice patterns concerning empirical treatment for vocal disorders. Supplemental content at jamaotolaryngology.com OBJECTIVE To examine how PCPs manage patients with dysphonia, especially with regard to laryngopharyngeal reflux. DESIGN, SETTING, AND PARTICIPANTS Prospective, questionnaire-based study by an academic laryngology practice among academic PCPs from all major US geographic regions. MAIN OUTCOMES AND MEASURES A 16-question web-based survey, distributed via e-mail, concerning management and possible empirical treatment options for patients with dysphonia. RESULTS Of 2441 physicians who received the e-mail broadcast, 314 (12.9%) completed the survey. Among those who completed the survey, 46.3% were family practitioners, 46.5% were trained in internal medicine, and 7.2% identified as specialists. Among all respondents, 64.% preferred to treat rather than immediately refer a patient with chronic hoarseness (symptoms persisting for >6 weeks) of unclear origin. Reflux medication (85.8%) and antihistamines (54.2%) were the most commonly selected choices for empirical treatment. Most physician respondents (79.2%) reported that they would treat chronic hoarseness with reflux medication in a patient without evidence of gastroesophageal reflux disease. CONCLUSIONS AND RELEVANCE Most PCPs who responded to our survey report empirically treating patients with chronic hoarseness of unknown origin. Many physician respondents were willing to empirically prescribe reflux medication as primary therapy, even when symptoms of gastroesophageal reflux disease were not present. These data suggest that PCPs strongly consider reflux a common cause of dysphonia and may empirically treat patients having dysphonia with reflux medication before referral. JAMA Otolaryngol Head Neck Surg. 14;1(3):192-196. doi:1.11/jamaoto.13.6533 Published online January, 14. Author Affiliations: Department of Otolaryngology Head and Neck Surgery, NYU Voice Center, New York University School of Medicine, New York, New York. Corresponding Author: Ryan C. Branski, PhD, Department of Otolaryngology Head and Neck Surgery, NYU Voice Center, New York University School of Medicine, 345 E 37th St, Ste 6, New York, NY 116 (ryan.branski@nyumc.org). Primary care providers have a crucial role in the diagnosis and treatment of voice disorders. With a lifetime prevalence of approximately %, 1,2 voice disorders are a considerable burden on the health care system. Primary care providers are often responsible for the initial management of these patients. Current approaches to the diagnosis and subsequent management of specific voice disorders by primary care physicians (PCPs) must be understood to create recommendations and guidelines for optimal treatment. Of the potential causative factors to be considered in a patient with dysphonia, laryngopharyngeal reflux (LPR) is particularly vexing because of its lack of association with typical gastroesophageal reflux symptoms. No consensus exists among physicians regarding the diagnosis and treatment of LPR. 3 For instance, in cases where LPR is suspected, empirical therapy with proton pump inhibitors has been recommended to confirm the diagnosis; however, guidelines suggest that this class of drug should not be prescribed to patients who lack recent signs and symptoms of gastroesophageal reflux disease (GERD). 4,5 Empirical treatment could prevent unnecessary referrals; however, it could also delay treatment for more serious causes of dysphonia such as laryngeal cancer. The objective of this study was to examine how PCPs manage patients with prolonged hoarseness of unclear origin. We hypothesize 192 JAMA Otolaryngology Head & Neck Surgery March 14 Volume 1, Number 3 jamaotolaryngology.com

Original Investigation Research that the primary care community may emphasize empirical treatment for reflux over potential evaluative methods or treatments in patients seen with dysphonia, even when other symptoms of reflux may be absent. Methods Survey Design The institutional review board at the New York University School of Medicine approved the present web-based, anonymous, deidentified survey. A 16-question survey was designed based on a literature review and clinical consensus (efigure in the Supplement). Specific questions were designed to address current practices related to the clinical practice guidelines on hoarseness, 6 as well as previous surveys addressing dysphonia. 7 Section 1 (questions 1-5) addressed physician willingness to empirically treat dysphonia of longer than 6 weeks, physician referral patterns, and empirical treatment choices. Section 2 (questions 6-1) specifically addressed the role of reflux in dysphonia, including the role for empirical treatment and subsequent evidence for dysphonia resolution after antireflux treatment. Section 3 (question 11) asked whether physicians had reviewed clinical practice guidelines in the literature pertaining to dysphonia. Section 4 (questions 12-16) included demographic questions such as geographic area, type of specialty, and years of clinical practice. Survey Distribution The survey was distributed via e-mail to family medicine physicians and general internists. These PCPs were chosen based on their academic affiliation with institutions across the United States. Academic departments that were contacted via e-mail were chosen at random, although an effort was made to distribute e-mails geographically according to predetermined US regions as outlined in the efigure in the Supplement. Data Accrual and Statistical Analysis All data were collected via an online data management system between February 5 and April 29, 13. The survey link was first distributed via e-mail to family practitioners and then to general internists in the same fashion. One initial e-mail was sent to potential respondents, followed by a reminder e-mail approximately 3 weeks later. Each physician group was then given an additional 3 weeks to complete the survey before the questionnaire was closed. Survey data were analyzed using the 1-sample z test to determine individual question significance and using Pearson product moment correlation χ 2 test to evaluate for response trends between physician groups. Results Table. Demographic Information Regarding the Cohort of Physician Respondents Variable Practice location, % Division 1 (New England): Maine, New Hampshire, Vermont, Rhode Island, Connecticut Division 2 (Mid-Atlantic): New York, Pennsylvania, New Jersey Division 3 (East North Central): Wisconsin, Michigan, Illinois, Indiana, Ohio Division 4 (West North Central): Missouri, North Dakota, South Dakota, Nebraska, Kansas, Minnesota, Iowa Division 5 (South Atlantic): Delaware, Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida Division 6 (East South Central): Kentucky, Tennessee, Mississippi, Alabama Division 7 (West South Central): Oklahoma, Texas, Arkansas, Louisiana Division 8 (Mountain): Idaho, Montana, Wyoming, Nevada, Utah, Colorado Value 1.8.7 18.2 16.9 Division 9 (Pacific): Alaska, Washington, Oregon, 8.9 California, Hawaii Practice setting, % Academic 84.7 Mixed 4.1 Private 11.1 Practice type, % Family medicine 46.3 General practitioner 32.2 General practitioner/hospitalist 8.8 Hospitalist 5.5 Specialist 7.2 Time since completion of training, y 15.9 Respondent Profile Of 2441 physicians who received the e-mail broadcast, 339 (13.9%) started the survey, and 314 (12.9%) completed the survey. Among those who completed the survey, 46.3% were family practitioners, 46.5% were trained in internal medicine (responded as general practitioner, general practitioner/ hospitalist, or hospitalist), and 7.2% identified as specialists. Across all specialties, most physicians (84.7%) worked in an academic setting. The mean time in practice since completion of residency was 15.9 years. Physicians responded from all over the country in a uniform distribution across 9 regions in the United States (Table). Treatment vs Referral Physician respondents were asked whether or not they would treat or immediately refer a patient with chronic hoarseness (symptoms persisting for >6 weeks) of unclear origin. In this cohort, 64.% of all respondents preferred to treat. Of those physicians who decided to initially treat patients with chronic hoarseness, 16.6% would treat for longer than 4 weeks before referral, 51.2% would treat for 3 to 4 weeks before referral,.4% would treat for 1 to 2 weeks before referral, and 1.4% would treat for less than 1 week before referral; 36.% of physicians referred patients immediately. Almost all physician respondents (99.4%) would refer to an otolaryngologist at some point, independent of their decision to treat or refer. Medication Choice for Empirical Treatment When asked what medications physicians prescribe routinely for patients with chronic hoarseness of unknown ori- 8.6 5.7 2.2 8. jamaotolaryngology.com JAMA Otolaryngology Head & Neck Surgery March 14 Volume 1, Number 3 193

Research Original Investigation Figure 1. Medications Prescribed 1 9 8 6 Respondents All Internal medicine Family medicine 1 None Antibiotics Corticosteroids Reflux Medication Antihistamines Other Prescribed Medication Reported medications prescribed to treat patients with persistent hoarseness of unknown origin. Figure 2. Causation and Treatment of Reflux A 6 B 6 1 Never Sometimes Most of the Time Always Reflux Is Causative for Hoarseness Unknown 1 None Some Half Most All Unknown Hoarseness Resolves With Antireflux Treatment Respondent views regarding the frequency that reflux is involved in hoarseness (A) and how often patients experience complete resolution of hoarseness with reflux management (B). gin, reflux medication (85.8%) and antihistamines (54.2%) were most commonly selected. Across all respondents, 41.% reported prescribing both reflux medication and antihistamines routinely. The most common other response was nasal corticosteroids. Approximately 15% of responding physicians reported that they do not routinely prescribe medications for patients with chronic hoarseness. Responses among physicians followed the same trend when selecting a preferential therapy (Figure 1). No statistically significant difference was observed in the prescription of reflux medication between physician groups (P =.48). Reflux and Its Contribution to Hoarseness Across all respondents, 61.3% reported that reflux was sometimes involved in the manifestation of hoarseness, and 27.% believed that reflux was involved most of the time (Figure 2A). In total, 55.7% thought that some of their patients improved with antireflux treatment, while 11.% of physicians perceived that most of their patients improved. When queried whether reflux medication led to complete resolution of symptoms, 56.6% believed that some of their patients completely resolved, while only 9.4% of physicians thought that most of their patients completely resolved (Figure 2B). Of those respondents who reported complete resolution of hoarseness with prescription of reflux medication, 57.6% reported that at least 3 weeks of therapy was necessary to achieve these results. Treatment Without Evidence of GERD When physicians were asked whether or not they would treat chronic hoarseness with reflux medication in a patient without symptoms consistent with GERD, 79.2% reported the affirmative (data not shown). This decision to treat reflux was statistically significant across all physician specialties (P <.1). Physician Experience With Treating Dysphonia Of the respondents, 74.2% treated fewer than 2 patients with hoarsenesspermonth,9.9%treated3to5,.6%treated6to 1, and 1.3% treated more than 1; 14.% of respondents treated no patients with hoarseness per month. In addition, 72.3% had not reviewed any clinical practice guidelines regarding the evaluation and management of patients with hoarseness. Discussion Empirical treatment of long-standing hoarseness by PCPs before visualization of the larynx is a potentially concerning is- 194 JAMA Otolaryngology Head & Neck Surgery March 14 Volume 1, Number 3 jamaotolaryngology.com

Original Investigation Research sue for otolaryngologists. In previous investigations, presumptive diagnoses made by general practitioners based on patient history were incongruent with final diagnoses made by otolaryngologists on laryngoscopic examination. 8 In the case of laryngeal carcinoma, evidence has shown that physician delay in diagnosis is a prognostic indicator associated with increased morbidity and more advanced disease. 9,1 Therefore, incorrect empirical treatment by PCPs could delay necessary interventions for more serious laryngeal pathologic conditions. In the present study, 64.% of physicians chose to empirically treat a patient with hoarseness of unknown origin lasting longer than 6 weeks, with a treatment regimen lasting up to 4 weeks. Although no evidence in the literature supports a precise duration to referral, most recommendations suggest referral after 2 weeks of persistent symptoms. 11,12 In contrast to our results, Turley and Cohen 7 reported that approximately two-thirds of PCPs elect to refer patients with dysphonia lasting more than 2 weeks. Given the differences in question design between the study by Turley and Cohen and the present data, it is difficult to determine exactly how long PCPs would wait before referral. However, it is reasonable to assume from the data presented herein that many PCPs are willing to attempt empirical treatment before a specialist has had the opportunity to visualize the larynx, despite the persistence of symptoms exceeding 6 weeks. Furthermore, 72.3% of physicians who responded reported never having read guidelines concerning the management of hoarseness. Although it would be difficult to draw any broad conclusions about national PCP practices from this survey, it is of concern that a substantial number of academic PCPs would choose to monitor and treat patients with dysphonia for extended periods without visualization of the larynx and without any guidelinebased treatment regimen. In our physician cohort, it is clear that most consider LPR a common cause of dysphonia of unclear origin and treat patients accordingly. Many of the symptoms associated with LPR such as dysphonia, throat clearing, and globus pharyngeus are nonspecific. In addition, LPR is difficult to diagnose even with visualization of the larynx. Recent evidence from our group has highlighted that patients with hoarseness who have been diagnosed as having LPR by PCPs and even general otolaryngologists and are subsequently referred to a specialty laryngology clinic often have significant missed pathologic conditions. 13 Concern is growing that physicians may be overemphasizing the role of LPR as causative of dysphonia. Possibly the most notable finding in this study was that 79.2% of respondents would empirically treat patients having dysphonia without evidence of concurrent GERD, a practice that is not supported by clinical practice guidelines. Furthermore, 85.8% of respondents prescribed reflux medication, yet only 9.4% found that this therapy provided complete resolution of symptoms. No conclusive evidence exists that proton pump inhibitor therapy is effective for LPR. Reviews of the literature have pointed to a substantial placebo effect in treatment trials for patients with LPR. 3,4 A 6 Cochrane review identified 6 randomized controlled trials that evaluated proton pump inhibitor therapy for LPR; all 6 studies reported a significant placebo response, and none met full criteria to determine treatment effectiveness. 14 After the Cochrane review, the most recent randomized trial (by Vaezi et al 15 ) also showed no statistical difference between the use of esomeprazole and placebo in patients with chronic posterior laryngitis. Because little evidence supports the treatment of LPR without the symptoms of GERD or without a laryngoscopic evaluation, these data suggest some level of disconnect in treatment strategies between the otolaryngology and primary care communities. However, published primary care literature advocates for a protocol-based approach to dysphonia management and calls for antireflux treatment only in the presence of GERD. 5 Therefore, it is clear that PCPs and otolaryngologists should be more vocal about a systematic approach to antireflux treatment in the setting of dysphonia within the primary care population. Previous efforts have informed the primary care community about the proper management of vocal disorders 12,16 ; however, it is clear that future communication between specialties, on a regional or national level, is still necessary. Our data show infrequent use of antibiotic therapy. The 9 clinical practice guideline 6 included a strong recommendation against antibiotic use for patients with dysphonia and a Cochrane review showed minimal benefit for antibiotic therapy in patients with chronic laryngitis. 17 In addition, an ever-present concern among physicians is the increasing rate of antibiotic-resistant bacteria; it is reassuring that most PCPs do not consider antibiotics an appropriate empirical treatment option for patients with dysphonia. The present study is not without limitations. As with all questionnaire-based studies, respondents may have misinterpreted questions. Physicians were asked to make concrete choices about patient treatment options with limited information about patient history. As such, it is possible that the respondents were forced into certain response choices because of the context of the question. This point is of particular concern when trying to apply any broad conclusions about PCP practice from this study sample alone. In addition, this study could be subject to selection bias; some physicians may have been more likely to participate because of their familiarity with voice issues. However, the demographic distribution of the respondents at least indicates that respondents have diverse training backgrounds and patient demographics. Conclusions Primary care physicians who responded to our survey preferred to treat patients with chronic hoarseness (>6 weeks) of unknown origin rather than refer immediately. These physician respondents treated hoarseness most commonly with reflux medication. In addition, they reported that they would treat hoarseness of unknown origin with antireflux treatment when symptoms of GERD were not present. These data indicate that PCPs strongly consider reflux a common cause of dysphonia, and many physicians may also believe that empirical treatment with reflux medication is indicated before referral. jamaotolaryngology.com JAMA Otolaryngology Head & Neck Surgery March 14 Volume 1, Number 3 195

Research Original Investigation ARTICLE INFORMATION Submitted for Publication: September 3, 13; final revision received November 4, 13; accepted December 3, 13. Published Online: January, 14. doi:1.11/jamaoto.13.6533. Author Contributions: Mr Ruiz and Dr Branski had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of data analysis. Study concept and design: All authors. Acquisition of data: Ruiz, Jeswani, Andrews. Analysis and interpretation of data: All authors. Drafting of the manuscript: Ruiz, Branski. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Ruiz, Branski. Administrative, technical, or material support: Ruiz, Jeswani, Andrews, Rafii, Paul. Conflict of Interest Disclosures: None reported. REFERENCES 1. Cohen SM. Self-reported impact of dysphonia in a primary care population. Laryngoscope. 1;1(1):22-32. 2. Roy N, Merrill RM, Gray SD, Smith EM. Voice disorders in the general population. Laryngoscope. 5;115(11):1988-1995. 3. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease. Curr Opin Gastroenterol. 1;26(4):389-394. 4. Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 5;294(12): 1534-15. 5. Feierabend RH, Shahram MN. Hoarseness in adults.am Fam Physician. 9;8(4):363-3. 6. Schwartz SR, Cohen SM, Dailey SH, et al. Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg. 9;141(3) (suppl 2):S1-S31. 7. Turley R, Cohen S. Primary care approach to dysphonia. Otolaryngol Head Neck Surg. 1;142(3):31-314. 8. Hoare TJ, Thomson HG, Proops DW. Detection of laryngeal cancer. J R Soc Med. 1993;86(7): 39-392. 9. Carvalho AL, Pintos J, Schlecht NF, et al. Predictive factors for diagnosis of advanced-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2;128(3):313-318. 1. Teppo H, Alho OP. Comorbidity and diagnostic delay in cancer of the larynx, tongue and pharynx. Oral Oncol. 9;45(8):692-695. 11. American Academy of Otolaryngology Head and Neck Surgery. Fact sheet: about your voice. http://www.entnet.org/healthinformation /aboutvoice.cfm. Accessed December 13, 13. 12. Rosen CA, Anderson D, Murry T. Evaluating hoarseness. Am Fam Physician. 1998;57(11):2775-2782. 13. Rafii B, Taliercio S, Achlatis S, Ruiz R, Amin MR, Branski RC. Incidence of underlying laryngeal pathology in patients initially diagnosed with laryngopharyngeal reflux. Laryngoscope. Inpress. 14. Hopkins C, Yousaf U, Pedersen M. Acid reflux treatment for hoarseness. Cochrane Database Syst Rev. 6;1:CD54. 15. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope.6;116(2): 254-26. 16. Mau T. Diagnostic evaluation and management of hoarseness. Med Clin North Am. 1;94(5):945-96. 17. Reveiz L, Cardona AF. Antibiotics for acute laryngitis in adults. Cochrane Database Syst Rev. 13;3:CD4783. 196 JAMA Otolaryngology Head & Neck Surgery March 14 Volume 1, Number 3 jamaotolaryngology.com